Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €122.37 EUR
Change Today +2.35 / 1.96%
Volume 1.6K
As of 12:44 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ACT) Snapshot

Open
€119.11
Previous Close
€120.02
Day High
€122.69
Day Low
€119.11
52 Week High
04/24/15 - €122.69
52 Week Low
05/19/14 - €67.23
Market Cap
14.0B
Average Volume 10 Days
1.3K
EPS TTM
--
Shares Outstanding
114.1M
EX-Date
05/12/15
P/E TM
--
Dividend
€1.30
Dividend Yield
0.80%
Current Stock Chart for ACTELION LTD-REG (ACT)

Related News

No related news articles were found.

actelion ltd-reg (ACT) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ACT) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Founded in 1997

actelion ltd-reg (ACT) Top Compensated Officers

Founder, Chief Executive Officer, Member of M...
Total Annual Compensation: SFr.2.7M
Compensation as of Fiscal Year 2014.

actelion ltd-reg (ACT) Key Developments

Actelion Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for 2015

Actelion Ltd. reported earnings results for the first quarter ended March 31, 2015. For the period, the company reported core operating income of CHF 218 million, core net income of CHF 185 million or CHF 1.61 per diluted share against core operating income of CHF 189 million, core net income of CHF 170 million or CHF 1.46 per diluted share a year ago. Operating income was CHF 190 million compared to CHF 153 million a year ago. Revenues were CHF 515 million compared to CHF 469 million a year ago. Operating cash inflow was CHF 94 million compared to CHF 96 million a year ago. The company reported net income of CHF 159 million, or CHF 1.38 per diluted share compared to CHF 128 million or CHF 1.09 per diluted share for the same quarter a year ago. Operating income was CHF 190 million, compared to CHF 153 million for the same quarter a year ago. Capital expenditure was CHF 7 million against CHF 6 million a year ago. Income before income tax expense was CHF 183 million. The company is now confident that, barring unforeseen events, core earnings growth for 2015 will be in the low double-digit percentage range, at constant exchange rates and excluding the benefit of 2014 US rebate reversals.

Actelion Seeks Acquisitions

Andre Muller, Chief Financial Officer of Actelion Ltd. (SWX:ATLN) said that the company is actively looking for acquisition opportunities but it will not pay an overly high price. Chief Financial Officer Andre Muller said "We are actively looking for M&A opportunities, However, we will remain disciplined especially in this M&A frenzy that we've seen in the recent past." The company's chief executive told it has not received any outside interest to buy the company.

Actelion Ltd. - Special Call

To discuss its specialty immunology pipeline compounds

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:GR €122.37 EUR +2.35

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $93.27 USD -0.81
H Lundbeck A/S kr132.10 DKK +2.00
Hikma Pharmaceuticals PLC 2,150 GBp +29.00
Pharmacyclics Inc $256.59 USD -0.51
UCB SA €69.02 EUR +0.03
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings 24.0x
Price/Sales 7.2x
Price/Book 7.5x
Price/Cash Flow 21.5x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit www.actelion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.